img

Global Neurodegenerative Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Neurodegenerative Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Neurodegenerative disease or neurodegeneration refers to the progressive damage or wear and tear of the nerve cells. Neurodegenerative disease causes loss of abilities like decision making and eventually memory loss.
The global Neurodegenerative Drugs market size was US$ 115030 million in 2022 and is forecast to a readjusted size of US$ 173000 million by 2034 with a CAGR of 5.9% during the forecast period 2024-2034.
The United States market for Neurodegenerative Drugs is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Neurodegenerative Drugs is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Neurodegenerative Drugs is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034..
The global key manufacturers of Neurodegenerative Drugs include Novartis, Pfizer, Merck Serono, Biogen Idec, TEVA, UCB, Boehringer Ingelheim, Sanofi and GlaxoSmithKline, etc. In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of Neurodegenerative Drugs, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Neurodegenerative Drugs by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Neurodegenerative Drugs market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Neurodegenerative Drugs market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Novartis
Pfizer
Merck Serono
Biogen Idec
TEVA
UCB
Boehringer Ingelheim
Sanofi
GlaxoSmithKline
Livzon Pharmaceutical
Haisco Pharmaceutical
Jingxin Pharmaceutical
Dongcheng Biochemicals
Hisun Pharmaceutical
Luye Pharma
Ark Pharmaceutical
Kanghong Pharmaceutical
Huahai Pharmaceutical
BORA PHARMACEUTICALS
By Type
NMDA
SSRIs
Dopamine Inhibitors
By Application
Parkinson’s Disease
Huntington Disease
Amyotrophic Lateral Sclerosis
Alzheimer’s Disease
Sales by Region
North America
United States
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Neurodegenerative Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Neurodegenerative Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neurodegenerative Drugs sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Neurodegenerative Drugs Definition
1.2 Market by Type
1.2.1 Global Neurodegenerative Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 NMDA
1.2.3 SSRIs
1.2.4 Dopamine Inhibitors
1.3 Market Segment by Application
1.3.1 Global Neurodegenerative Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Parkinson’s Disease
1.3.3 Huntington Disease
1.3.4 Amyotrophic Lateral Sclerosis
1.3.5 Alzheimer’s Disease
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Neurodegenerative Drugs Sales
2.1 Global Neurodegenerative Drugs Revenue Estimates and Forecasts 2018-2034
2.2 Global Neurodegenerative Drugs Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Neurodegenerative Drugs Revenue by Region
2.3.1 Global Neurodegenerative Drugs Revenue by Region (2018-2024)
2.3.2 Global Neurodegenerative Drugs Revenue by Region (2024-2034)
2.4 Global Neurodegenerative Drugs Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Neurodegenerative Drugs Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Neurodegenerative Drugs Sales Quantity by Region
2.6.1 Global Neurodegenerative Drugs Sales Quantity by Region (2018-2024)
2.6.2 Global Neurodegenerative Drugs Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Neurodegenerative Drugs Sales Quantity by Manufacturers
3.1.1 Global Neurodegenerative Drugs Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Neurodegenerative Drugs Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Neurodegenerative Drugs Sales in 2022
3.2 Global Neurodegenerative Drugs Revenue by Manufacturers
3.2.1 Global Neurodegenerative Drugs Revenue by Manufacturers (2018-2024)
3.2.2 Global Neurodegenerative Drugs Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Neurodegenerative Drugs Revenue in 2022
3.3 Global Neurodegenerative Drugs Sales Price by Manufacturers
3.4 Global Key Players of Neurodegenerative Drugs, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Neurodegenerative Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Neurodegenerative Drugs, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Neurodegenerative Drugs, Product Offered and Application
3.8 Global Key Manufacturers of Neurodegenerative Drugs, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Neurodegenerative Drugs Sales Quantity by Type
4.1.1 Global Neurodegenerative Drugs Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Neurodegenerative Drugs Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Neurodegenerative Drugs Sales Quantity Market Share by Type (2018-2034)
4.2 Global Neurodegenerative Drugs Revenue by Type
4.2.1 Global Neurodegenerative Drugs Historical Revenue by Type (2018-2024)
4.2.2 Global Neurodegenerative Drugs Forecasted Revenue by Type (2024-2034)
4.2.3 Global Neurodegenerative Drugs Revenue Market Share by Type (2018-2034)
4.3 Global Neurodegenerative Drugs Price by Type
4.3.1 Global Neurodegenerative Drugs Price by Type (2018-2024)
4.3.2 Global Neurodegenerative Drugs Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Neurodegenerative Drugs Sales Quantity by Application
5.1.1 Global Neurodegenerative Drugs Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Neurodegenerative Drugs Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Neurodegenerative Drugs Sales Quantity Market Share by Application (2018-2034)
5.2 Global Neurodegenerative Drugs Revenue by Application
5.2.1 Global Neurodegenerative Drugs Historical Revenue by Application (2018-2024)
5.2.2 Global Neurodegenerative Drugs Forecasted Revenue by Application (2024-2034)
5.2.3 Global Neurodegenerative Drugs Revenue Market Share by Application (2018-2034)
5.3 Global Neurodegenerative Drugs Price by Application
5.3.1 Global Neurodegenerative Drugs Price by Application (2018-2024)
5.3.2 Global Neurodegenerative Drugs Price Forecast by Application (2024-2034)
6 North America
6.1 North America Neurodegenerative Drugs Sales by Company
6.1.1 North America Neurodegenerative Drugs Revenue by Company (2018-2024)
6.1.2 North America Neurodegenerative Drugs Sales Quantity by Company (2018-2024)
6.2 North America Neurodegenerative Drugs Market Size by Type
6.2.1 North America Neurodegenerative Drugs Sales Quantity by Type (2018-2034)
6.2.2 North America Neurodegenerative Drugs Revenue by Type (2018-2034)
6.3 North America Neurodegenerative Drugs Market Size by Application
6.3.1 North America Neurodegenerative Drugs Sales Quantity by Application (2018-2034)
6.3.2 North America Neurodegenerative Drugs Revenue by Application (2018-2034)
6.4 North America Neurodegenerative Drugs Market Size by Country
6.4.1 North America Neurodegenerative Drugs Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Neurodegenerative Drugs Revenue by Country (2018-2034)
6.4.3 North America Neurodegenerative Drugs Sales Quantity by Country (2018-2034)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Neurodegenerative Drugs Sales by Company
7.1.1 Europe Neurodegenerative Drugs Sales Quantity by Company (2018-2024)
7.1.2 Europe Neurodegenerative Drugs Revenue by Company (2018-2024)
7.2 Europe Neurodegenerative Drugs Market Size by Type
7.2.1 Europe Neurodegenerative Drugs Sales Quantity by Type (2018-2034)
7.2.2 Europe Neurodegenerative Drugs Revenue by Type (2018-2034)
7.3 Europe Neurodegenerative Drugs Market Size by Application
7.3.1 Europe Neurodegenerative Drugs Sales Quantity by Application (2018-2034)
7.3.2 Europe Neurodegenerative Drugs Revenue by Application (2018-2034)
7.4 Europe Neurodegenerative Drugs Market Size by Country
7.4.1 Europe Neurodegenerative Drugs Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Neurodegenerative Drugs Revenue by Country (2018-2034)
7.4.3 Europe Neurodegenerative Drugs Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Neurodegenerative Drugs Sales by Company
8.1.1 China Neurodegenerative Drugs Sales Quantity by Company (2018-2024)
8.1.2 China Neurodegenerative Drugs Revenue by Company (2018-2024)
8.2 China Neurodegenerative Drugs Market Size by Type
8.2.1 China Neurodegenerative Drugs Sales Quantity by Type (2018-2034)
8.2.2 China Neurodegenerative Drugs Revenue by Type (2018-2034)
8.3 China Neurodegenerative Drugs Market Size by Application
8.3.1 China Neurodegenerative Drugs Sales Quantity by Application (2018-2034)
8.3.2 China Neurodegenerative Drugs Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Neurodegenerative Drugs Sales by Company
9.1.1 APAC Neurodegenerative Drugs Sales Quantity by Company (2018-2024)
9.1.2 APAC Neurodegenerative Drugs Revenue by Company (2018-2024)
9.2 APAC Neurodegenerative Drugs Market Size by Type
9.2.1 APAC Neurodegenerative Drugs Sales Quantity by Type (2018-2034)
9.2.2 APAC Neurodegenerative Drugs Revenue by Type (2018-2034)
9.3 APAC Neurodegenerative Drugs Market Size by Application
9.3.1 APAC Neurodegenerative Drugs Sales Quantity by Application (2018-2034)
9.3.2 APAC Neurodegenerative Drugs Revenue by Application (2018-2034)
9.4 APAC Neurodegenerative Drugs Market Size by Region
9.4.1 APAC Neurodegenerative Drugs Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Neurodegenerative Drugs Revenue by Region (2018-2034)
9.4.3 APAC Neurodegenerative Drugs Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Neurodegenerative Drugs Sales by Company
10.1.1 Middle East, Africa and Latin America Neurodegenerative Drugs Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Neurodegenerative Drugs Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Neurodegenerative Drugs Market Size by Type
10.2.1 Middle East, Africa and Latin America Neurodegenerative Drugs Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Neurodegenerative Drugs Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Neurodegenerative Drugs Market Size by Application
10.3.1 Middle East, Africa and Latin America Neurodegenerative Drugs Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Neurodegenerative Drugs Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Neurodegenerative Drugs Market Size by Country
10.4.1 Middle East, Africa and Latin America Neurodegenerative Drugs Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Neurodegenerative Drugs Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Neurodegenerative Drugs Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Novartis
11.1.1 Novartis Company Information
11.1.2 Novartis Overview
11.1.3 Novartis Neurodegenerative Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Novartis Neurodegenerative Drugs Products and Services
11.1.5 Novartis Neurodegenerative Drugs SWOT Analysis
11.1.6 Novartis Recent Developments
11.2 Pfizer
11.2.1 Pfizer Company Information
11.2.2 Pfizer Overview
11.2.3 Pfizer Neurodegenerative Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 Pfizer Neurodegenerative Drugs Products and Services
11.2.5 Pfizer Neurodegenerative Drugs SWOT Analysis
11.2.6 Pfizer Recent Developments
11.3 Merck Serono
11.3.1 Merck Serono Company Information
11.3.2 Merck Serono Overview
11.3.3 Merck Serono Neurodegenerative Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Merck Serono Neurodegenerative Drugs Products and Services
11.3.5 Merck Serono Neurodegenerative Drugs SWOT Analysis
11.3.6 Merck Serono Recent Developments
11.4 Biogen Idec
11.4.1 Biogen Idec Company Information
11.4.2 Biogen Idec Overview
11.4.3 Biogen Idec Neurodegenerative Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Biogen Idec Neurodegenerative Drugs Products and Services
11.4.5 Biogen Idec Neurodegenerative Drugs SWOT Analysis
11.4.6 Biogen Idec Recent Developments
11.5 TEVA
11.5.1 TEVA Company Information
11.5.2 TEVA Overview
11.5.3 TEVA Neurodegenerative Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 TEVA Neurodegenerative Drugs Products and Services
11.5.5 TEVA Neurodegenerative Drugs SWOT Analysis
11.5.6 TEVA Recent Developments
11.6 UCB
11.6.1 UCB Company Information
11.6.2 UCB Overview
11.6.3 UCB Neurodegenerative Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 UCB Neurodegenerative Drugs Products and Services
11.6.5 UCB Neurodegenerative Drugs SWOT Analysis
11.6.6 UCB Recent Developments
11.7 Boehringer Ingelheim
11.7.1 Boehringer Ingelheim Company Information
11.7.2 Boehringer Ingelheim Overview
11.7.3 Boehringer Ingelheim Neurodegenerative Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.7.4 Boehringer Ingelheim Neurodegenerative Drugs Products and Services
11.7.5 Boehringer Ingelheim Neurodegenerative Drugs SWOT Analysis
11.7.6 Boehringer Ingelheim Recent Developments
11.8 Sanofi
11.8.1 Sanofi Company Information
11.8.2 Sanofi Overview
11.8.3 Sanofi Neurodegenerative Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.8.4 Sanofi Neurodegenerative Drugs Products and Services
11.8.5 Sanofi Neurodegenerative Drugs SWOT Analysis
11.8.6 Sanofi Recent Developments
11.9 GlaxoSmithKline
11.9.1 GlaxoSmithKline Company Information
11.9.2 GlaxoSmithKline Overview
11.9.3 GlaxoSmithKline Neurodegenerative Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.9.4 GlaxoSmithKline Neurodegenerative Drugs Products and Services
11.9.5 GlaxoSmithKline Neurodegenerative Drugs SWOT Analysis
11.9.6 GlaxoSmithKline Recent Developments
11.10 Livzon Pharmaceutical
11.10.1 Livzon Pharmaceutical Company Information
11.10.2 Livzon Pharmaceutical Overview
11.10.3 Livzon Pharmaceutical Neurodegenerative Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.10.4 Livzon Pharmaceutical Neurodegenerative Drugs Products and Services
11.10.5 Livzon Pharmaceutical Neurodegenerative Drugs SWOT Analysis
11.10.6 Livzon Pharmaceutical Recent Developments
11.11 Haisco Pharmaceutical
11.11.1 Haisco Pharmaceutical Company Information
11.11.2 Haisco Pharmaceutical Overview
11.11.3 Haisco Pharmaceutical Neurodegenerative Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.11.4 Haisco Pharmaceutical Neurodegenerative Drugs Products and Services
11.11.5 Haisco Pharmaceutical Recent Developments
11.12 Jingxin Pharmaceutical
11.12.1 Jingxin Pharmaceutical Company Information
11.12.2 Jingxin Pharmaceutical Overview
11.12.3 Jingxin Pharmaceutical Neurodegenerative Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.12.4 Jingxin Pharmaceutical Neurodegenerative Drugs Products and Services
11.12.5 Jingxin Pharmaceutical Recent Developments
11.13 Dongcheng Biochemicals
11.13.1 Dongcheng Biochemicals Company Information
11.13.2 Dongcheng Biochemicals Overview
11.13.3 Dongcheng Biochemicals Neurodegenerative Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.13.4 Dongcheng Biochemicals Neurodegenerative Drugs Products and Services
11.13.5 Dongcheng Biochemicals Recent Developments
11.14 Hisun Pharmaceutical
11.14.1 Hisun Pharmaceutical Company Information
11.14.2 Hisun Pharmaceutical Overview
11.14.3 Hisun Pharmaceutical Neurodegenerative Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.14.4 Hisun Pharmaceutical Neurodegenerative Drugs Products and Services
11.14.5 Hisun Pharmaceutical Recent Developments
11.15 Luye Pharma
11.15.1 Luye Pharma Company Information
11.15.2 Luye Pharma Overview
11.15.3 Luye Pharma Neurodegenerative Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.15.4 Luye Pharma Neurodegenerative Drugs Products and Services
11.15.5 Luye Pharma Recent Developments
11.16 Ark Pharmaceutical
11.16.1 Ark Pharmaceutical Company Information
11.16.2 Ark Pharmaceutical Overview
11.16.3 Ark Pharmaceutical Neurodegenerative Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.16.4 Ark Pharmaceutical Neurodegenerative Drugs Products and Services
11.16.5 Ark Pharmaceutical Recent Developments
11.17 Kanghong Pharmaceutical
11.17.1 Kanghong Pharmaceutical Company Information
11.17.2 Kanghong Pharmaceutical Overview
11.17.3 Kanghong Pharmaceutical Neurodegenerative Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.17.4 Kanghong Pharmaceutical Neurodegenerative Drugs Products and Services
11.17.5 Kanghong Pharmaceutical Recent Developments
11.18 Huahai Pharmaceutical
11.18.1 Huahai Pharmaceutical Company Information
11.18.2 Huahai Pharmaceutical Overview
11.18.3 Huahai Pharmaceutical Neurodegenerative Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.18.4 Huahai Pharmaceutical Neurodegenerative Drugs Products and Services
11.18.5 Huahai Pharmaceutical Recent Developments
11.19 BORA PHARMACEUTICALS
11.19.1 BORA PHARMACEUTICALS Company Information
11.19.2 BORA PHARMACEUTICALS Overview
11.19.3 BORA PHARMACEUTICALS Neurodegenerative Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.19.4 BORA PHARMACEUTICALS Neurodegenerative Drugs Products and Services
11.19.5 BORA PHARMACEUTICALS Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Neurodegenerative Drugs Value Chain Analysis
12.2 Neurodegenerative Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Neurodegenerative Drugs Production Mode & Process
12.4 Neurodegenerative Drugs Sales and Marketing
12.4.1 Neurodegenerative Drugs Sales Channels
12.4.2 Neurodegenerative Drugs Distributors
12.5 Neurodegenerative Drugs Customers
13 Market Dynamics
13.1 Neurodegenerative Drugs Industry Trends
13.2 Neurodegenerative Drugs Market Drivers
13.3 Neurodegenerative Drugs Market Challenges
13.4 Neurodegenerative Drugs Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Neurodegenerative Drugs Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of NMDA
Table 3. Major Manufacturers of SSRIs
Table 4. Major Manufacturers of Dopamine Inhibitors
Table 5. Global Neurodegenerative Drugs Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Neurodegenerative Drugs Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 7. Global Neurodegenerative Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 8. Global Neurodegenerative Drugs Revenue Market Share by Region (2018-2024)
Table 9. Global Neurodegenerative Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 10. Global Neurodegenerative Drugs Revenue Market Share by Region (2024-2034)
Table 11. Global Neurodegenerative Drugs Sales Quantity by Region: 2018 VS 2022 VS 2034 (MT)
Table 12. Global Neurodegenerative Drugs Sales by Region (2018-2024) & (MT)
Table 13. Global Neurodegenerative Drugs Sales Market Share by Region (2018-2024)
Table 14. Global Neurodegenerative Drugs Sales by Region (2024-2034) & (MT)
Table 15. Global Neurodegenerative Drugs Sales Market Share by Region (2024-2034)
Table 16. Global Neurodegenerative Drugs Sales Quantity by Manufacturers (2018-2024) & (MT)
Table 17. Global Neurodegenerative Drugs Sales Quantity Share by Manufacturers (2018-2024)
Table 18. Global Neurodegenerative Drugs Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 19. Global Neurodegenerative Drugs Revenue Share by Manufacturers (2018-2024)
Table 20. Global Neurodegenerative Drugs Price by Manufacturers 2018-2024 (US$/MT)
Table 21. Global Key Players of Neurodegenerative Drugs, Industry Ranking, 2021 VS 2022
Table 22. Global Neurodegenerative Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Neurodegenerative Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neurodegenerative Drugs as of 2022)
Table 24. Global Key Manufacturers of Neurodegenerative Drugs, Manufacturing Base Distribution and Headquarters
Table 25. Global Key Manufacturers of Neurodegenerative Drugs, Product Offered and Application
Table 26. Global Key Manufacturers of Neurodegenerative Drugs, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Neurodegenerative Drugs Sales Quantity by Type (2018-2024) & (MT)
Table 29. Global Neurodegenerative Drugs Sales Quantity by Type (2024-2034) & (MT)
Table 30. Global Neurodegenerative Drugs Sales Quantity Share by Type (2018-2024)
Table 31. Global Neurodegenerative Drugs Sales Quantity Share by Type (2024-2034)
Table 32. Global Neurodegenerative Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 33. Global Neurodegenerative Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 34. Global Neurodegenerative Drugs Revenue Share by Type (2018-2024)
Table 35. Global Neurodegenerative Drugs Revenue Share by Type (2024-2034)
Table 36. Neurodegenerative Drugs Price by Type (2018-2024) & (US$/MT)
Table 37. Global Neurodegenerative Drugs Price Forecast by Type (2024-2034) & (US$/MT)
Table 38. Global Neurodegenerative Drugs Sales Quantity by Application (2018-2024) & (MT)
Table 39. Global Neurodegenerative Drugs Sales Quantity by Application (2024-2034) & (MT)
Table 40. Global Neurodegenerative Drugs Sales Quantity Share by Application (2018-2024)
Table 41. Global Neurodegenerative Drugs Sales Quantity Share by Application (2024-2034)
Table 42. Global Neurodegenerative Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 43. Global Neurodegenerative Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 44. Global Neurodegenerative Drugs Revenue Share by Application (2018-2024)
Table 45. Global Neurodegenerative Drugs Revenue Share by Application (2024-2034)
Table 46. Neurodegenerative Drugs Price by Application (2018-2024) & (US$/MT)
Table 47. Global Neurodegenerative Drugs Price Forecast by Application (2024-2034) & (US$/MT)
Table 48. North America Neurodegenerative Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 49. North America Neurodegenerative Drugs Sales Quantity by Company (2018-2024) & (MT)
Table 50. North America Neurodegenerative Drugs Sales Quantity by Type (2018-2024) & (MT)
Table 51. North America Neurodegenerative Drugs Sales Quantity by Type (2024-2034) & (MT)
Table 52. North America Neurodegenerative Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 53. North America Neurodegenerative Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 54. North America Neurodegenerative Drugs Sales Quantity by Application (2018-2024) & (MT)
Table 55. North America Neurodegenerative Drugs Sales Quantity by Application (2024-2034) & (MT)
Table 56. North America Neurodegenerative Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 57. North America Neurodegenerative Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 58. North America Neurodegenerative Drugs Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 59. North America Neurodegenerative Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 60. North America Neurodegenerative Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 61. North America Neurodegenerative Drugs Sales Quantity by Country (2018-2024) & (MT)
Table 62. North America Neurodegenerative Drugs Sales Quantity by Country (2024-2034) & (MT)
Table 63. Europe Neurodegenerative Drugs Sales Quantity by Company (2018-2024) & (MT)
Table 64. Europe Neurodegenerative Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 65. Europe Neurodegenerative Drugs Sales Quantity by Type (2018-2024) & (MT)
Table 66. Europe Neurodegenerative Drugs Sales Quantity by Type (2024-2034) & (MT)
Table 67. Europe Neurodegenerative Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 68. Europe Neurodegenerative Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 69. Europe Neurodegenerative Drugs Sales Quantity by Application (2018-2024) & (MT)
Table 70. Europe Neurodegenerative Drugs Sales Quantity by Application (2024-2034) & (MT)
Table 71. Europe Neurodegenerative Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 72. Europe Neurodegenerative Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 73. Europe Neurodegenerative Drugs Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 74. Europe Neurodegenerative Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 75. Europe Neurodegenerative Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 76. Europe Neurodegenerative Drugs Sales Quantity by Country (2018-2024) & (MT)
Table 77. Europe Neurodegenerative Drugs Sales Quantity by Country (2024-2034) & (MT)
Table 78. China Neurodegenerative Drugs Sales Quantity by Company (2018-2024) & (MT)
Table 79. China Neurodegenerative Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 80. China Neurodegenerative Drugs Sales Quantity by Type (2018-2024) & (MT)
Table 81. China Neurodegenerative Drugs Sales Quantity by Type (2024-2034) & (MT)
Table 82. China Neurodegenerative Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 83. China Neurodegenerative Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 84. China Neurodegenerative Drugs Sales Quantity by Application (2018-2024) & (MT)
Table 85. China Neurodegenerative Drugs Sales Quantity by Application (2024-2034) & (MT)
Table 86. China Neurodegenerative Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 87. China Neurodegenerative Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 88. APAC Neurodegenerative Drugs Sales Quantity by Company (2018-2024) & (MT)
Table 89. APAC Neurodegenerative Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 90. APAC Neurodegenerative Drugs Sales Quantity by Type (2018-2024) & (MT)
Table 91. APAC Neurodegenerative Drugs Sales Quantity by Type (2024-2034) & (MT)
Table 92. APAC Neurodegenerative Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 93. APAC Neurodegenerative Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 94. APAC Neurodegenerative Drugs Sales Quantity by Application (2018-2024) & (MT)
Table 95. APAC Neurodegenerative Drugs Sales Quantity by Application (2024-2034) & (MT)
Table 96. APAC Neurodegenerative Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 97. APAC Neurodegenerative Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 98. APAC Neurodegenerative Drugs Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 99. APAC Neurodegenerative Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 100. APAC Neurodegenerative Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 101. APAC Neurodegenerative Drugs Sales Quantity by Region (2018-2024) & (MT)
Table 102. APAC Neurodegenerative Drugs Sales Quantity by Region (2024-2034) & (MT)
Table 103. Middle East, Africa and Latin America Neurodegenerative Drugs Sales Quantity by Company (2018-2024) & (MT)
Table 104. Middle East, Africa and Latin America Neurodegenerative Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 105. Middle East, Africa and Latin America Neurodegenerative Drugs Sales Quantity by Type (2018-2024) & (MT)
Table 106. Middle East, Africa and Latin America Neurodegenerative Drugs Sales Quantity by Type (2024-2034) & (MT)
Table 107. Middle East, Africa and Latin America Neurodegenerative Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 108. Middle East, Africa and Latin America Neurodegenerative Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 109. Middle East, Africa and Latin America Neurodegenerative Drugs Sales Quantity by Application (2018-2024) & (MT)
Table 110. Middle East, Africa and Latin America Neurodegenerative Drugs Sales Quantity by Application (2024-2034) & (MT)
Table 111. Middle East, Africa and Latin America Neurodegenerative Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 112. Middle East, Africa and Latin America Neurodegenerative Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 113. Middle East, Africa and Latin America Neurodegenerative Drugs Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 114. Middle East, Africa and Latin America Neurodegenerative Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 115. Middle East, Africa and Latin America Neurodegenerative Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 116. Middle East, Africa and Latin America Neurodegenerative Drugs Sales Quantity by Country (2018-2024) & (MT)
Table 117. Middle East, Africa and Latin America Neurodegenerative Drugs Sales Quantity by Country (2024-2034) & (MT)
Table 118. Novartis Company Information
Table 119. Novartis Description and Overview
Table 120. Novartis Neurodegenerative Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (US$/MT) and Gross Margin (2018-2024)
Table 121. Novartis Neurodegenerative Drugs Product and Services
Table 122. Novartis Neurodegenerative Drugs SWOT Analysis
Table 123. Novartis Recent Developments
Table 124. Pfizer Company Information
Table 125. Pfizer Description and Overview
Table 126. Pfizer Neurodegenerative Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (US$/MT) and Gross Margin (2018-2024)
Table 127. Pfizer Neurodegenerative Drugs Product and Services
Table 128. Pfizer Neurodegenerative Drugs SWOT Analysis
Table 129. Pfizer Recent Developments
Table 130. Merck Serono Company Information
Table 131. Merck Serono Description and Overview
Table 132. Merck Serono Neurodegenerative Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (US$/MT) and Gross Margin (2018-2024)
Table 133. Merck Serono Neurodegenerative Drugs Product and Services
Table 134. Merck Serono Neurodegenerative Drugs SWOT Analysis
Table 135. Merck Serono Recent Developments
Table 136. Biogen Idec Company Information
Table 137. Biogen Idec Description and Overview
Table 138. Biogen Idec Neurodegenerative Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (US$/MT) and Gross Margin (2018-2024)
Table 139. Biogen Idec Neurodegenerative Drugs Product and Services
Table 140. Biogen Idec Neurodegenerative Drugs SWOT Analysis
Table 141. Biogen Idec Recent Developments
Table 142. TEVA Company Information
Table 143. TEVA Description and Overview
Table 144. TEVA Neurodegenerative Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (US$/MT) and Gross Margin (2018-2024)
Table 145. TEVA Neurodegenerative Drugs Product and Services
Table 146. TEVA Neurodegenerative Drugs SWOT Analysis
Table 147. TEVA Recent Developments
Table 148. UCB Company Information
Table 149. UCB Description and Overview
Table 150. UCB Neurodegenerative Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (US$/MT) and Gross Margin (2018-2024)
Table 151. UCB Neurodegenerative Drugs Product and Services
Table 152. UCB Neurodegenerative Drugs SWOT Analysis
Table 153. UCB Recent Developments
Table 154. Boehringer Ingelheim Company Information
Table 155. Boehringer Ingelheim Description and Overview
Table 156. Boehringer Ingelheim Neurodegenerative Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (US$/MT) and Gross Margin (2018-2024)
Table 157. Boehringer Ingelheim Neurodegenerative Drugs Product and Services
Table 158. Boehringer Ingelheim Neurodegenerative Drugs SWOT Analysis
Table 159. Boehringer Ingelheim Recent Developments
Table 160. Sanofi Company Information
Table 161. Sanofi Description and Overview
Table 162. Sanofi Neurodegenerative Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (US$/MT) and Gross Margin (2018-2024)
Table 163. Sanofi Neurodegenerative Drugs Product and Services
Table 164. Sanofi Neurodegenerative Drugs SWOT Analysis
Table 165. Sanofi Recent Developments
Table 166. GlaxoSmithKline Company Information
Table 167. GlaxoSmithKline Description and Overview
Table 168. GlaxoSmithKline Neurodegenerative Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (US$/MT) and Gross Margin (2018-2024)
Table 169. GlaxoSmithKline Neurodegenerative Drugs Product and Services
Table 170. GlaxoSmithKline Neurodegenerative Drugs SWOT Analysis
Table 171. GlaxoSmithKline Recent Developments
Table 172. Livzon Pharmaceutical Company Information
Table 173. Livzon Pharmaceutical Description and Overview
Table 174. Livzon Pharmaceutical Neurodegenerative Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (US$/MT) and Gross Margin (2018-2024)
Table 175. Livzon Pharmaceutical Neurodegenerative Drugs Product and Services
Table 176. Livzon Pharmaceutical Neurodegenerative Drugs SWOT Analysis
Table 177. Livzon Pharmaceutical Recent Developments
Table 178. Haisco Pharmaceutical Company Information
Table 179. Haisco Pharmaceutical Description and Overview
Table 180. Haisco Pharmaceutical Neurodegenerative Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (US$/MT) and Gross Margin (2018-2024)
Table 181. Haisco Pharmaceutical Neurodegenerative Drugs Product and Services
Table 182. Haisco Pharmaceutical Recent Developments
Table 183. Jingxin Pharmaceutical Company Information
Table 184. Jingxin Pharmaceutical Description and Overview
Table 185. Jingxin Pharmaceutical Neurodegenerative Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (US$/MT) and Gross Margin (2018-2024)
Table 186. Jingxin Pharmaceutical Neurodegenerative Drugs Product and Services
Table 187. Jingxin Pharmaceutical Recent Developments
Table 188. Dongcheng Biochemicals Company Information
Table 189. Dongcheng Biochemicals Description and Overview
Table 190. Dongcheng Biochemicals Neurodegenerative Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (US$/MT) and Gross Margin (2018-2024)
Table 191. Dongcheng Biochemicals Neurodegenerative Drugs Product and Services
Table 192. Dongcheng Biochemicals Recent Developments
Table 193. Hisun Pharmaceutical Company Information
Table 194. Hisun Pharmaceutical Description and Overview
Table 195. Hisun Pharmaceutical Neurodegenerative Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (US$/MT) and Gross Margin (2018-2024)
Table 196. Hisun Pharmaceutical Neurodegenerative Drugs Product and Services
Table 197. Hisun Pharmaceutical Recent Developments
Table 198. Luye Pharma Company Information
Table 199. Luye Pharma Description and Overview
Table 200. Luye Pharma Neurodegenerative Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (US$/MT) and Gross Margin (2018-2024)
Table 201. Luye Pharma Neurodegenerative Drugs Product and Services
Table 202. Luye Pharma Recent Developments
Table 203. Ark Pharmaceutical Company Information
Table 204. Ark Pharmaceutical Description and Overview
Table 205. Ark Pharmaceutical Neurodegenerative Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (US$/MT) and Gross Margin (2018-2024)
Table 206. Ark Pharmaceutical Neurodegenerative Drugs Product and Services
Table 207. Ark Pharmaceutical Recent Developments
Table 208. Kanghong Pharmaceutical Company Information
Table 209. Kanghong Pharmaceutical Description and Overview
Table 210. Kanghong Pharmaceutical Neurodegenerative Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (US$/MT) and Gross Margin (2018-2024)
Table 211. Kanghong Pharmaceutical Neurodegenerative Drugs Product and Services
Table 212. Kanghong Pharmaceutical Recent Developments
Table 213. Huahai Pharmaceutical Company Information
Table 214. Huahai Pharmaceutical Description and Overview
Table 215. Huahai Pharmaceutical Neurodegenerative Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (US$/MT) and Gross Margin (2018-2024)
Table 216. Huahai Pharmaceutical Neurodegenerative Drugs Product and Services
Table 217. Huahai Pharmaceutical Recent Developments
Table 218. BORA PHARMACEUTICALS Company Information
Table 219. BORA PHARMACEUTICALS Description and Overview
Table 220. BORA PHARMACEUTICALS Neurodegenerative Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (US$/MT) and Gross Margin (2018-2024)
Table 221. BORA PHARMACEUTICALS Neurodegenerative Drugs Product and Services
Table 222. BORA PHARMACEUTICALS Recent Developments
Table 223. Key Raw Materials Lists
Table 224. Raw Materials Key Suppliers Lists
Table 225. Neurodegenerative Drugs Distributors List
Table 226. Neurodegenerative Drugs Customers List
Table 227. Neurodegenerative Drugs Market Trends
Table 228. Neurodegenerative Drugs Market Drivers
Table 229. Neurodegenerative Drugs Market Challenges
Table 230. Neurodegenerative Drugs Market Restraints
Table 231. Research Programs/Design for This Report
Table 232. Key Data Information from Secondary Sources
Table 233. Key Data Information from Primary Sources
List of Figures
Figure 1. Neurodegenerative Drugs Product Picture
Figure 2. Global Neurodegenerative Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Neurodegenerative Drugs Market Share by Type in 2022 & 2034
Figure 4. NMDA Product Picture
Figure 5. SSRIs Product Picture
Figure 6. Dopamine Inhibitors Product Picture
Figure 7. Global Neurodegenerative Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 8. Global Neurodegenerative Drugs Market Share by Application in 2022 & 2034
Figure 9. Parkinson’s Disease
Figure 10. Huntington Disease
Figure 11. Amyotrophic Lateral Sclerosis
Figure 12. Alzheimer’s Disease
Figure 13. Neurodegenerative Drugs Report Years Considered
Figure 14. Global Neurodegenerative Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 15. Global Neurodegenerative Drugs Revenue 2018-2034 (US$ Million)
Figure 16. Global Neurodegenerative Drugs Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 17. Global Neurodegenerative Drugs Sales Quantity 2018-2034 (MT)
Figure 18. Global Neurodegenerative Drugs Sales Quantity Market Share by Region (2018-2024)
Figure 19. Global Neurodegenerative Drugs Sales Quantity Market Share by Region (2024-2034)
Figure 20. North America Neurodegenerative Drugs Sales Quantity YoY (2018-2034) & (MT)
Figure 21. North America Neurodegenerative Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 22. Europe Neurodegenerative Drugs Sales Quantity YoY (2018-2034) & (MT)
Figure 23. Europe Neurodegenerative Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 24. China Neurodegenerative Drugs Sales Quantity YoY (2018-2034) & (MT)
Figure 25. China Neurodegenerative Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 26. APAC Neurodegenerative Drugs Sales Quantity YoY (2018-2034) & (MT)
Figure 27. APAC Neurodegenerative Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 28. Middle East, Africa and Latin America Neurodegenerative Drugs Sales Quantity YoY (2018-2034) & (MT)
Figure 29. Middle East, Africa and Latin America Neurodegenerative Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 30. The Top 10 and Top 5 Players Market Share by Neurodegenerative Drugs Sales Quantity in 2022
Figure 31. The Top 10 and Top 5 Players Market Share by Neurodegenerative Drugs Revenue in 2022
Figure 32. Neurodegenerative Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 33. Global Neurodegenerative Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 34. Global Neurodegenerative Drugs Revenue Market Share by Type (2018-2034)
Figure 35. Global Neurodegenerative Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 36. Global Neurodegenerative Drugs Revenue Market Share by Application (2018-2034)
Figure 37. North America Neurodegenerative Drugs Revenue Market Share by Company in 2022
Figure 38. North America Neurodegenerative Drugs Sales Quantity Market Share by Company in 2022
Figure 39. North America Neurodegenerative Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 40. North America Neurodegenerative Drugs Revenue Market Share by Type (2018-2034)
Figure 41. North America Neurodegenerative Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 42. North America Neurodegenerative Drugs Revenue Market Share by Application (2018-2034)
Figure 43. North America Neurodegenerative Drugs Revenue Share by Country (2018-2034)
Figure 44. North America Neurodegenerative Drugs Sales Quantity Share by Country (2018-2034)
Figure 45. United States Neurodegenerative Drugs Revenue (2018-2034) & (US$ Million)
Figure 46. Canada Neurodegenerative Drugs Revenue (2018-2034) & (US$ Million)
Figure 47. Europe Neurodegenerative Drugs Sales Quantity Market Share by Company in 2022
Figure 48. Europe Neurodegenerative Drugs Revenue Market Share by Company in 2022
Figure 49. Europe Neurodegenerative Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 50. Europe Neurodegenerative Drugs Revenue Market Share by Type (2018-2034)
Figure 51. Europe Neurodegenerative Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 52. Europe Neurodegenerative Drugs Revenue Market Share by Application (2018-2034)
Figure 53. Europe Neurodegenerative Drugs Revenue Share by Country (2018-2034)
Figure 54. Europe Neurodegenerative Drugs Sales Quantity Share by Country (2018-2034)
Figure 55. Germany Neurodegenerative Drugs Revenue (2018-2034) & (US$ Million)
Figure 56. France Neurodegenerative Drugs Revenue (2018-2034) & (US$ Million)
Figure 57. U.K. Neurodegenerative Drugs Revenue (2018-2034) & (US$ Million)
Figure 58. Italy Neurodegenerative Drugs Revenue (2018-2034) & (US$ Million)
Figure 59. Russia Neurodegenerative Drugs Revenue (2018-2034) & (US$ Million)
Figure 60. China Neurodegenerative Drugs Sales Quantity Market Share by Company in 2022
Figure 61. China Neurodegenerative Drugs Revenue Market Share by Company in 2022
Figure 62. China Neurodegenerative Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 63. China Neurodegenerative Drugs Revenue Market Share by Type (2018-2034)
Figure 64. China Neurodegenerative Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 65. China Neurodegenerative Drugs Revenue Market Share by Application (2018-2034)
Figure 66. APAC Neurodegenerative Drugs Sales Quantity Market Share by Company in 2022
Figure 67. APAC Neurodegenerative Drugs Revenue Market Share by Company in 2022
Figure 68. APAC Neurodegenerative Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 69. APAC Neurodegenerative Drugs Revenue Market Share by Type (2018-2034)
Figure 70. APAC Neurodegenerative Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 71. APAC Neurodegenerative Drugs Revenue Market Share by Application (2018-2034)
Figure 72. APAC Neurodegenerative Drugs Revenue Share by Region (2018-2034)
Figure 73. APAC Neurodegenerative Drugs Sales Quantity Share by Region (2018-2034)
Figure 74. Japan Neurodegenerative Drugs Revenue (2018-2034) & (US$ Million)
Figure 75. South Korea Neurodegenerative Drugs Revenue (2018-2034) & (US$ Million)
Figure 76. China Taiwan Neurodegenerative Drugs Revenue (2018-2034) & (US$ Million)
Figure 77. Southeast Asia Neurodegenerative Drugs Revenue (2018-2034) & (US$ Million)
Figure 78. India Neurodegenerative Drugs Revenue (2018-2034) & (US$ Million)
Figure 79. Middle East, Africa and Latin America Neurodegenerative Drugs Sales Quantity Market Share by Company in 2022
Figure 80. Middle East, Africa and Latin America Neurodegenerative Drugs Revenue Market Share by Company in 2022
Figure 81. Middle East, Africa and Latin America Neurodegenerative Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 82. Middle East, Africa and Latin America Neurodegenerative Drugs Revenue Market Share by Type (2018-2034)
Figure 83. Middle East, Africa and Latin America Neurodegenerative Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 84. Middle East, Africa and Latin America Neurodegenerative Drugs Revenue Market Share by Application (2018-2034)
Figure 85. Middle East, Africa and Latin America Neurodegenerative Drugs Sales Quantity Share by Country (2018-2034)
Figure 86. Middle East, Africa and Latin America Neurodegenerative Drugs Revenue Share by Country (2018-2034)
Figure 87. Brazil Neurodegenerative Drugs Revenue (2018-2034) & (US$ Million)
Figure 88. Mexico Neurodegenerative Drugs Revenue (2018-2034) & (US$ Million)
Figure 89. Turkey Neurodegenerative Drugs Revenue (2018-2034) & (US$ Million)
Figure 90. Israel Neurodegenerative Drugs Revenue (2018-2034) & (US$ Million)
Figure 91. GCC Countries Neurodegenerative Drugs Revenue (2018-2034) & (US$ Million)
Figure 92. Neurodegenerative Drugs Value Chain
Figure 93. Neurodegenerative Drugs Production Process
Figure 94. Channels of Distribution (Direct Vs Distribution)
Figure 95. Distributors Profiles
Figure 96. Bottom-up and Top-down Approaches for This Report
Figure 97. Data Triangulation
Figure 98. Key Executives Interviewed